Eric D. Shaff - 19 May 2023 Form 4 Insider Report for Sigilon Therapeutics, Inc.

Role
Director
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
19 May 2023
Net transactions value
$0
Form type
4
Filing time
22 May 2023, 16:20:16 UTC
Previous filing
07 Feb 2023
Next filing
11 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGTX Stock Option (Right to Buy) Award $0 +8,888 $0.000000 8,888 19 May 2023 Common Stock 8,888 $0.6366 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 19, 2024.